AstraZeneca Discontinues Brazikumab Inflammatory Bowel Disease Development Program
By Anthony O. Goriainoff AstraZeneca said Thursday that it was discontinuing the brazikumab inflammatory bowel disease development program after reviewing its development timeline as well as... | June 1, 2023